gave | Friday, May 28, 2021 – 17:01 | Last Updated: 28 05 2021 – 17:01
The first phase of clinical trials of isoquercetin against coronavirus in Canada has been successfully completed. Second phase studies were approved by the Canadian Ministry of Health. In Turkey, it was announced that the production of isoquercetin, which has approximately 5 times more improved bioabsorption and approximately 18 times more bioavailability than the quercetin molecule, has started.
Quercetin is among the most popular flavonoid supplements. It has neuroprotective, cardioprotective, chemopreventive, antioxidant, anti-inflammatory, antiviral and anti-allergic properties. Its efficacy has been demonstrated.Quercetin is not the dominant form seen in nature and its bioavailability is weak.In many scientific studies, it has been shown that the bioabsorption of isoquercetin can be up to 5 times and its bioavailability up to 18 times.In numerous clinical studies and hundreds of scientific publications, quercetin can be used for both protection in high-risk populations and remdesivir or convalescent Existing evidence has been presented for its use for the treatment of coronavirus patients by assisting pharmacological agents such as plasma.It has been proven that SARS-CoV-2 and other coronaviruses stop cell entry and proliferation, balance coagulation and excessive immune response. It is a pleasing development that it has been produced with national means, because this molecule can be produced in a few centers in the world. Even though I have the BioNTech vaccine, I use quercetin support especially to avoid being affected by the variants.”